Építés alatt – nem éles oldal
Belépés
Leállítva1/2. fázis

Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections

A legfontosabb adatok

Ki végzi
Shenzhen Geno-Immune Medical Institute
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Leállítva
Fázis
1/2. fázis
Résztvevők
100 fő vett részt
Kezdés
2026. jún. 1.
Befejezés
2026. júl. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • pathogen-specific CTLs
A regiszteradat frissítve
2026. november 2.

Ki vehet részt

Életkor
6 hónap – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 21 feltétel megnézéseKevesebb

Ki vehet részt

  • Subjects with or without hematopoietic stem cell transplantation / organ transplant recipients need to meet the following conditions:
  • Evidence of CMV, EBV, ADV, BKV or known pathogen infection (viral DNA, immunohistochemical cytology positive); contraindications or invalid to anti-microbial drugs
  • Subjects with virus DNA increased in the 2 consecutive peripheral blood samples (≥ 1000 genomic copies/ml blood) at least 24 hours apart
  • Initial hematopoietic reconstitution: neutrophils (ANC) ≥ 0.5x109 / L, platelet (PLT) ≥ 20x109 / L
  • Patients with pahogen disease (organ/ tissue infiltration) symptoms, fever, diarrhea, or lymphadenopathy, regardless of the level of peripheral blood virus DNA, and confirmed by the presence of viral DNA or microbial antigens within body fluid or biopsy
  • The subject / guardian has signed a written consent form before any trial begins; Proper renal and hepatic functions (ULN denotes "upper limit of normal range"):
  • Creatinine ≤ 2*ULN
  • Bilirubin ≤ 2*ULN
  • SGOT ≤ 3*ULN
  • SGPT≤ 3*ULN; If CTL is not from the patient's own, then the provider of CTLs needs to meet the following criteria:
  • Did not receive chemotherapy or radiotherapy within 4 weeks prior to blood collection, and did not take any steroids for the previous week, did not use Penicillin or β-lactam antibiotics, or the lowest dose of other antibiotics
  • White blood cells ≥ 3,500 / μl, lymphocytes ≥ 750 / μl
  • Obtain a signed informed consent from the patient and / or the guardian or the donor of the BMT recipient
  • Human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) or tuberculosis (TB) test is negative
  • Physical examination in line with the standard of healthy blood donors

Ki nem vehet részt

  • Subject participated in other investigational somatic cell therapies within past 30 days
  • Subject infected with HCV (HCV antibody positive), HBV (HBsAg positive), HIV (HIV antibody positive), or HTLV (HTLV antibody positive)
  • GVHD (graft-versus-host disease) performance score at II-IV
  • Subject is albumin-intolerant
  • Subject with life expectancy less than 4 weeks
  • Subject with positive pregnancy test result

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Epstein Barr Virus (EBV) or Cytomegalovirus (CMV) infection results in significant morbidity and mortality in hematopoietic stem cell transplantation (HSCT) patients. HSCT patients often face opportunistic infections due to the immunosuppressive state during transplantation. Antimicrobial drugs are usually used for prophylactic purposes and for treatment after early detectable infections. Unfortunately, some patients develop resistance to such drug treatment. In addition to HSCT patient, immune compromised patient may also be victim to opportunistic infections. Many infections can be effectively managed by functional immune recovery. In this study, the safety and efficacy of microbial-specific cytotoxic T lymphocytes (CTLs) will be investigated.

A vizsgálat csoportja

  • Infusion of pathogen-specific CTLsA vizsgált kezelés

    Repetitive CTL infusions to treat microbial infections

    Kezelés: pathogen-specific CTLs

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Phase I/II Multicenter Trial of Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
A regiszteradat frissítve
2026. november 2.